Therefore, these specific inhibitors or bioactive substances, known to target the NLRP3 inflammasome, may be a novel strategy for treating not only kidney dysfunction but even other system involvement of SLE. The gene discussed is NLRP3; the disease is systemic lupus erythematosus.